James C. Yao - Concepedia

Author

James C. Yao

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Andrew Hendifar, Asif Rashid, Haller, Daniel G., J C Yao, J Yao, J. C. Yao, J. Yao, J.C. Yao, JA Yao, JAMES C. YAO

587

Publications

38.4K

Citations

H-Index

107

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Moffitt Cancer Center Dana-Farber Cancer Institute Novartis (Switzerland)Charité - Universitätsmedizin Berlin

About

James C. Yao is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	44	89	11.1K
2	Health Sciences	16	21	1.2K
3	Public Health	3	3	290
4	Engineering	1	1	44
5	Biochemistry	1	1	12

James C. Yao

198

Publications

30.7K

Citations

H-Index

Page 1

	Year	Citations
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States Arvind Dasari, Chan Shen, Daniel M. Halperin, JAMA Oncology	2017	3.4K
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, New England Journal of Medicine	2017	3K
Everolimus for Advanced Pancreatic Neuroendocrine Tumors James C. Yao, Manisha H. Shah, Tetsuhide Ito, New England Journal of Medicine	2011	2.8K
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study James C. Yao, Nicola Fazio, Simron Singh, The Lancet OncologyGastrointestinal OncologyMedicinePathologyCancer Treatment	2015	1.2K
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Marianne Pavel, John D. Hainsworth, Éric Baudin, The Lancet Carcinoid SyndromeOctreotide Long-acting RepeatableMedicinePharmacologyPathology	2011	1K
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Journal of Clinical Oncology Octreotide LarSurgical OncologyPancreatic CancerPhase Ii TrialGastrointestinal Oncology	2009	648
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study James C. Yao, Alexandria T. Phan, David Z. Chang, Journal of Clinical Oncology	2008	645
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas Maria A. Kouvaraki, Jaffer A. Ajani, Paulo M. Hoff, Journal of Clinical Oncology	2004	605
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors Pamela L. Kunz, Diane Reidy‐Lagunes, Lowell Anthony, Pancreas Tumor BiologyGliomaMedicineNeuroendocrine DisorderPathology	2013	582
NANETS Treatment Guidelines Matthew H. Kulke, Lowell Anthony, David Bushnell, Pancreas Surgical OncologyOncologyPancreatic CancerGastrointestinal OncologySymptomatic Treatment	2010	569

Page 1